Exelixis says cabozantinib sNDA no longer Advisory Committee discussion subject

Exelixis (EXEL) announced it has been notified by the U.S. Food and Drug Administration that the supplemental New Drug Application for cabozantinib for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic will no longer be the subject of discussion at an Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by FDA with a Prescription Drug User Fee Act action date of April 3, the company stated.